Total Payments
$4,337
2024 Payments
$2,011
Companies
40
Transactions
221
Medicare Patients
12,045
Medicare Billing
$2.5M
Payment Breakdown by Category
Food & Beverage$4,256 (98.1%)
Education$81.31 (1.9%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,256 | 214 | 98.1% |
| Education | $81.31 | 7 | 1.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $547.54 | 28 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $319.80 | 16 | $0 (2024) |
| Janssen Biotech, Inc. | $319.59 | 19 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $260.06 | 16 | $0 (2024) |
| GENZYME CORPORATION | $255.18 | 12 | $0 (2024) |
| Merck Sharp & Dohme LLC | $241.61 | 11 | $0 (2024) |
| PFIZER INC. | $229.09 | 18 | $0 (2024) |
| Gilead Sciences, Inc. | $198.32 | 10 | $0 (2024) |
| SOBI, INC | $152.77 | 6 | $0 (2024) |
| Celgene Corporation | $146.05 | 7 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,011 | 96 | Novartis Pharmaceuticals Corporation ($248.29) |
| 2023 | $1,310 | 64 | Novartis Pharmaceuticals Corporation ($213.38) |
| 2022 | $262.77 | 15 | Amgen Inc. ($56.32) |
| 2021 | $23.29 | 1 | Seagen Inc. ($23.29) |
| 2020 | $50.55 | 3 | GENZYME CORPORATION ($21.81) |
| 2019 | $142.89 | 6 | Medtronic Vascular, Inc. ($67.66) |
| 2018 | $109.85 | 7 | PFIZER INC. ($45.75) |
| 2017 | $427.00 | 29 | PFIZER INC. ($107.26) |
All Payment Transactions
221 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $25.99 | General |
| Category: Oncology | ||||||
| 12/20/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $21.18 | General |
| Category: Hematology | ||||||
| 12/06/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $20.64 | General |
| 12/02/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $15.00 | General |
| Category: Oncology | ||||||
| 11/25/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $19.29 | General |
| Category: ONCOLOGY | ||||||
| 11/22/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $14.80 | General |
| 11/18/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $26.14 | General |
| Category: Oncology | ||||||
| 11/15/2024 | GENZYME CORPORATION | ALTUVIIIO (Biological), ALPROLIX | Food and Beverage | In-kind items and services | $23.39 | General |
| Category: Hematology | ||||||
| 11/11/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $21.86 | General |
| Category: Oncology | ||||||
| 11/06/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $12.73 | General |
| Category: Oncology | ||||||
| 11/05/2024 | Janssen Biotech, Inc. | CARVYKTI (Drug) | Food and Beverage | In-kind items and services | $23.31 | General |
| Category: Oncology | ||||||
| 11/04/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $22.36 | General |
| Category: ONCOLOGY | ||||||
| 11/01/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $31.38 | General |
| Category: Oncology | ||||||
| 10/31/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $27.49 | General |
| Category: Oncology | ||||||
| 10/30/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $22.29 | General |
| Category: Oncology | ||||||
| 10/28/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $19.07 | General |
| 10/24/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $20.10 | General |
| Category: Hematology | ||||||
| 10/21/2024 | GENZYME CORPORATION | ALPROLIX (Biological), ALTUVIIIO | Food and Beverage | In-kind items and services | $24.09 | General |
| Category: Hematology | ||||||
| 10/21/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $24.02 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/18/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $18.73 | General |
| Category: ONCOLOGY | ||||||
| 10/16/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $17.75 | General |
| Category: ONCOLOGY | ||||||
| 10/14/2024 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug) | Food and Beverage | In-kind items and services | $18.24 | General |
| Category: Oncology | ||||||
| 10/11/2024 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $21.55 | General |
| Category: Oncology | ||||||
| 10/07/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $29.46 | General |
| Category: ONCOLOGY | ||||||
| 10/02/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $24.36 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 50 | 2,887 | 72,863 | $4.0M | $779,001 |
| 2022 | 55 | 2,705 | 75,398 | $3.9M | $527,366 |
| 2021 | 58 | 3,104 | 72,092 | $3.6M | $584,946 |
| 2020 | 65 | 3,349 | 76,139 | $4.2M | $650,566 |
Total Patients
12,045
Total Services
296,492
Medicare Billing
$2.5M
Procedure Codes
228
All Medicare Procedures & Services
228 procedure records from CMS Medicare Utilization — Page 3 of 10
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2022 | 16 | 5,070 | $1.1M | $167,343 | 14.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 243 | 553 | $203,504 | $50,381 | 24.8% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 24 | 2,760 | $161,340 | $46,580 | 28.9% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2022 | 11 | 288 | $388,224 | $36,670 | 9.4% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2022 | 16 | 13,000 | $260,000 | $32,439 | 12.5% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2022 | 24 | 28 | $134,456 | $31,967 | 23.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 71 | 268 | $189,476 | $27,590 | 14.6% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2022 | 91 | 98 | $104,566 | $17,081 | 16.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 78 | 78 | $55,302 | $12,611 | 22.8% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2022 | 18 | 82 | $301,350 | $11,763 | 3.9% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 78 | 207 | $64,791 | $10,518 | 16.2% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2022 | 14 | 49 | $7,840 | $7,816 | 99.7% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2022 | 12 | 118 | $24,898 | $6,868 | 27.6% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 257 | 789 | $28,404 | $6,036 | 21.3% |
| J9070 | Cyclophosphamide, 100 mg | Office | 2022 | 11 | 270 | $54,810 | $5,408 | 9.9% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2022 | 66 | 418 | $45,144 | $5,074 | 11.2% |
| 71260 | Ct scan of chest with contrast | Office | 2022 | 95 | 103 | $84,563 | $4,653 | 5.5% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2022 | 139 | 446 | $28,544 | $4,653 | 16.3% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2022 | 35 | 90 | $30,960 | $4,520 | 14.6% |
| J1756 | Injection, iron sucrose, 1 mg | Office | 2022 | 37 | 27,100 | $54,200 | $4,441 | 8.2% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2022 | 26 | 30 | $19,710 | $2,844 | 14.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 269 | 929 | $18,580 | $2,741 | 14.8% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2022 | 32 | 91 | $14,287 | $2,097 | 14.7% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2022 | 29 | 123 | $12,300 | $1,988 | 16.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 63 | 180 | $17,280 | $1,951 | 11.3% |
About Dr. Nandita Rao, MD
Dr. Nandita Rao, MD is a Hematology & Oncology healthcare provider based in Plano, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/22/2007. The National Provider Identifier (NPI) number assigned to this provider is 1669507372.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nandita Rao, MD has received a total of $4,337 in payments from pharmaceutical and medical device companies, with $2,011 received in 2024. These payments were reported across 221 transactions from 40 companies. The most common payment nature is "Food and Beverage" ($4,256).
As a Medicare-enrolled provider, Rao has provided services to 12,045 Medicare beneficiaries, totaling 296,492 services with total Medicare billing of $2.5M. Data is available for 4 years (2020–2023), covering 228 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Plano, TX
- Active Since 02/22/2007
- Last Updated 12/11/2008
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1669507372
Products in Payments
- KEYTRUDA (Biological) $221.98
- KISQALI (Drug) $206.92
- DARZALEX (Biological) $168.02
- OPDIVO (Biological) $156.53
- Lenvima (Drug) $142.94
- BESREMI (Drug) $133.10
- OJJAARA (Drug) $132.15
- VERZENIO (Drug) $120.24
- LUMAKRAS (Drug) $113.05
- REBLOZYL (Biological) $102.97
- Enhertu (Drug) $96.67
- MEKINIST (Drug) $94.69
- IMFINZI (Biological) $86.44
- CABLIVI (Biological) $79.37
- DOPTELET (Drug) $77.40
- SARCLISA (Biological) $74.26
- ENHERTU (Biological) $67.92
- ClosureFast (Device) $67.66
- LYNPARZA (Drug) $63.66
- VONVENDI (Biological) $62.69
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Plano
Ruben Saez, Md, MD
Hematology & Oncology — Payments: $117,913
Hematology & Oncology $117,913
Deepna Jaiswal, D.o, D.O
Hematology & Oncology — Payments: $50,892
Hematology & Oncology $50,892
Dr. Thuy Le, M.d, M.D
Hematology & Oncology — Payments: $22,323
Hematology & Oncology $22,323
Andrew Kovoor, Md, MD
Hematology & Oncology — Payments: $13,233
Hematology & Oncology $13,233
Virginia Kinsella, Md, MD
Hematology & Oncology — Payments: $13,129
Hematology & Oncology $13,129
Dr. Wendy Mahone-Johnson, Md, MD
Hematology & Oncology — Payments: $8,818
Hematology & Oncology $8,818